StreetInsider.com News Articles

Alumis SLE trial fails primary endpoints; subgroup data guides Phase 3

Tue, 01 Sep 2026 07:32:55 -0400

Alumis Inc. (Nasdaq: ALMS) announced that its Phase 2b LUMUS trial of envudeucitinib for moderate-to-severe systemic lupus erythematosus (SLE) did not meet its primary and secondary endpoints in the overall trial population, according to a company statement.

The trial enrolled 408 patients who received one of three envudeucitinib doses or placebo over 48 weeks. The primary endpoint measured overall disease activity using the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) at Week 48.

A prespecified subgroup of patients with high interferon gene signature (IFNGS-high) showed responses on the primary endpoint and key secondary measures, including CLASI-50, SRI-4, and Lupus Low

Alumis SLE trial fails primary endpoints; subgroup data guides Phase 3

Tue, 01 Sep 2026 07:32:55 -0400

A prespecified subgroup of patients with high interferon gene signature (IFNGS-high) showed responses on the primary endpoint and key secondary measures, including CLASI-50, SRI-4, and Lupus Low

Alumis SLE trial fails primary endpoints; subgroup data guides Phase 3

Tue, 01 Sep 2026 07:32:55 -0400

A prespecified subgroup of patients with high interferon gene signature (IFNGS-high) showed responses on the primary endpoint and key secondary measures, including CLASI-50, SRI-4, and Lupus Low

Alumis SLE trial fails primary endpoints; subgroup data guides Phase 3

Tue, 01 Sep 2026 07:32:55 -0400

A prespecified subgroup of patients with high interferon gene signature (IFNGS-high) showed responses on the primary endpoint and key secondary measures, including CLASI-50, SRI-4, and Lupus Low

Alumis SLE trial fails primary endpoints; subgroup data guides Phase 3

Tue, 01 Sep 2026 07:32:55 -0400

A prespecified subgroup of patients with high interferon gene signature (IFNGS-high) showed responses on the primary endpoint and key secondary measures, including CLASI-50, SRI-4, and Lupus Low

Alumis (ALMS) Halted, News Pending

Tue, 01 Sep 2026 07:26:44 -0400

Alumis (NASDAQ: ALMS) Halted, News Pending

H.C. Wainwright Reiterates Neutral Rating on Alumis Inc (ALMS)

Mon, 17 Aug 2026 06:43:00 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Neutral rating and $25.00 price target on Alumis Inc (NASDAQ: ALMS).

The analyst commented: "Alumis is prioritizing Sjögren’s disease and systemic lupus erythematosus (SLE) as the next envu indications, contingent on 3Q26 LUMUS results and capital allocation. A convincing SLE result would provide clinical support for maximal TYK2 inhibition in Type I interferon-driven disease and justify follow-on development in related indications, giving Alumis a second path beyond psoriasis (PsO). A weak or mixed result would leave most near-term value tied to PsO, where the 4Q26 NDA and ONWARD3 durability support a strong approval

Form SCHEDULE 13D ALUMIS INC. Filed by: Foresite Capital Fund VI LP

Mon, 17 Aug 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20260817/26934405.html

Form SCHEDULE 13D ALUMIS INC. Filed by: Foresite Capital Fund VI LP

Mon, 17 Aug 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20260817/26934405.html

Form 10-Q ALUMIS INC. For: Jun 30

Thu, 13 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260813/26921542.html

Form 10-Q ALUMIS INC. For: Jun 30

Thu, 13 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260813/26921542.html

Form 8-K ALUMIS INC. For: Aug 13

Thu, 13 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26920970.html

Form 8-K ALUMIS INC. For: Aug 13

Thu, 13 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26920970.html

Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

Thu, 13 Aug 2026 16:01:00 -0400

– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO –

– Alumis remains on track to submit its New Drug Application to FDA for envudeucitinib in moderate-to-severe plaque psoriasis (PsO) in Q4 2026 –